Aspira Women’s Health Announces New Time for its Fourth Quarter and 2023 Year End Earnings Results and Call
25 März 2024 - 1:00PM
Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq:
AWH), a bio-analytical based women’s health company focused on the
development of gynecologic disease diagnostic tools, today
announced that the Company will report its financial results for
the three months and year ended December 31, 2023, on Thursday,
March 28, 2024. Management will also host a conference call at an
updated time of 8:30 am ET to discuss financial results and provide
a corporate update. Details for the call are as follows:
Conference
Call & Webcast Details: |
Date: |
|
Thursday, March 28, 2024 |
Time: |
|
8:30 am ET (NEW TIME) |
Toll Free: |
|
877-407-4018 |
International: |
|
201-689-8471 |
Webcast: |
|
Click HERE |
Call Me™: |
|
Click HERE |
|
|
|
Participants can use the Guest dial-in numbers above and be
answered by an operator OR participants can click the Call Me link
for instant telephone access to the event. The Call Me link will be
made active 15 minutes prior to the scheduled start time.
A replay of the webcast will also be available on the Events
& Presentation page of the Aspira Women’s Health Investor
Relations website.
About Aspira Women’s Health Inc.Aspira Women’s
Health Inc. is dedicated to the discovery, development, and
commercialization of noninvasive, AI-powered tests to aid in the
diagnosis of gynecologic diseases.
OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM.
Together, they provide the only comprehensive portfolio of blood
tests to aid in the detection of ovarian cancer for the 1.2+
million American women diagnosed with an adnexal mass each year.
OvaWatch provides a negative predictive value of 99% and is used to
assess ovarian cancer risk for women where initial clinical
assessment indicates the mass is indeterminate or benign, and thus
surgery may be premature or unnecessary. Ova1Plus is comprised of
two FDA-cleared tests, Ova1® and Overa®, to assess the risk of
ovarian malignancy in women planned for
surgery.
Our in-development test pipeline is designed to expand our
ovarian cancer portfolio and addresses the tremendous need for
noninvasive diagnostics for endometriosis, a debilitating disease
that impacts millions of women worldwide. In ovarian cancer, our
OvaMDxSM risk assessment is designed to combine microRNA and
protein biomarkers with patient data to further enhance the
sensitivity and specificity of our current tests. In endometriosis,
EndoCheckSM is the first-ever noninvasive test designed to identify
endometriomas, one of the most commonly occurring forms of
endometriosis. The EndoMDxSM test is designed to combine microRNA
and protein biomarkers with patient data to identify all
endometriosis.
Investor Relations Contact: Torsten
Hombeck, Ph.D. Chief Financial Officer Aspira Women’s
Health Investors@aspirawh.com
Aspira Womans Health (NASDAQ:AWH)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Aspira Womans Health (NASDAQ:AWH)
Historical Stock Chart
Von Jun 2023 bis Jun 2024